Polygon Therapeutics Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 8

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 5

Polygon Therapeutics General Information

Description

Operator of a biotech company intended for the treatment of cardiovascular diseases. The company provides a therapeutic development program to improve cardiovascular disease care and mitigate the damage inflicted on the heart, enabling the healthcare industry to reduce the burden of cardiovascular diseases by providing early-stage treatment to patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 26 Rue Laffitie
  • Levallois-Perret
  • 75009 Paris
  • France
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Vertical(s)
Corporate Office
  • 26 Rue Laffitie
  • Levallois-Perret
  • 75009 Paris
  • France

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Polygon Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Accelerator/Incubator 17-Apr-2024 Completed Pre-Clinical Trials
2. Seed Round Completed Startup
1. Accelerator/Incubator 01-Jan-2022 Completed Startup
To view Polygon Therapeutics’s complete valuation and funding history, request access »

Polygon Therapeutics Patents

Polygon Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023381445-A1 Anti-cd8 alpha depleting antibodies Pending 17-Nov-2022
EP-4619436-A1 Anti-cd8 alpha depleting antibodies Pending 17-Nov-2022
US-12522659-B2 Anti-cd8 alpha depleting antibodies Active 17-Nov-2022
US-20250277036-A1 Anti-cd8 alpha depleting antibodies Active 17-Nov-2022
US-20260098091-A1 Anti-cd8 alpha depleting antibodies Pending 17-Nov-2022 C07K16/2815
To view Polygon Therapeutics’s complete patent history, request access »

Polygon Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Polygon Therapeutics Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
EIT Health Accelerator/Incubator
Agoranov Accelerator/Incubator
Aloe Private Equity PE/Buyout Minority
Audacia Growth/Expansion Minority
Sorbonne Venture Venture Capital Minority
To view Polygon Therapeutics’s complete investors history, request access »

Polygon Therapeutics FAQs

  • When was Polygon Therapeutics founded?

    Polygon Therapeutics was founded in 2021.

  • Where is Polygon Therapeutics headquartered?

    Polygon Therapeutics is headquartered in Paris, France.

  • What is the size of Polygon Therapeutics?

    Polygon Therapeutics has 8 total employees.

  • What industry is Polygon Therapeutics in?

    Polygon Therapeutics’s primary industry is Drug Discovery.

  • Is Polygon Therapeutics a private or public company?

    Polygon Therapeutics is a Private company.

  • What is Polygon Therapeutics’s current revenue?

    The current revenue for Polygon Therapeutics is .

  • How much funding has Polygon Therapeutics raised over time?

    Polygon Therapeutics has raised $7.5M.

  • Who are Polygon Therapeutics’s investors?

    EIT Health, Agoranov, Aloe Private Equity, Audacia, and Sorbonne Venture have invested in Polygon Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process